Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Background In patients with early-stage triple-negative breast cancer, the phase 3
KEYNOTE-522 trial showed significant improvements in pathological complete response …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast
cancer, but what distinguishes responders from non-responders is unclear. Because ICB …

Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from …